Coris BioConcept, a Walloon company specializing in in vitro diagnostics launched a new rapid diagnostic platform. It uses a novel microfluidic technology to conduct analyzes in multiplex mode. The platform allows to simultaneously identify multiple clinical parameters from a single blood or urine sample.
Thanks to the platform, the time to make a diagnosis can be shortened. The first applications of the platform will allow to identify the bacteria that cause sepsis and to determine whether these bacteria have antibiotic resistance. The platform is made up of an analytical instrument and microfluidic chips in which the tests are performed.
The Walloon Region (via BioWin) and the European program FP7 supported the development of this new diagnostic tool. The platform enables Coris BioConcept to position itself in the new market of rapid multiplex testing. The first two applications for the diagnosis of sepsis will be clinically validated later this year and will become available on the market within the next two years.
Founded in 1996, Coris BioConcept is a company active in the biotechnology sector and specializes in the development, production and marketing of rapid diagnostic tests. Coris BioConcept grows steadily since it was founded and is continually expanding its range of products, which are being sold in over 70 countries.
The main competitors in Belgium for this new diagnostic platform of Coris BioConcept are Roche Diagnostics (Vilvoorde) and Biocartis (Mechelen), who presumably will place similar products on the market.
